Figure 3From: Vascular disrupting agent for neovascular age related macular degeneration: a pilot study of the safety and efficacy of intravenous combretastatin a-4 phosphate Mean changes in visual acuity and central retinal thickness during the study period in the study eyes (top) and the fellow eyes (bottom). Back to article page